Cargando…

A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report

Chemical treatment is the vital pattern for colon cancer patients after surgery. Irinotecan and tegafur-gimeracil-oteracil potassium (S-1) combined chemotherapy is effective on metastatic colorectal cancer (mCRC). Nevertheless, patients receiving this combined chemotherapy might suffer the adverse d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang-Xi, Le, Ke-Jia, Zhang, Chi, Cui, Min, Zhou, Hong, Su, Ying-Jie, Gu, Zhi-Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798791/ https://www.ncbi.nlm.nih.gov/pubmed/35117192 http://dx.doi.org/10.21037/tcr.2019.11.39

Ejemplares similares

Tegafur/gimeracil/oteracil‐induced eosinophilic pneumonia
por: Sumi, Toshiyuki, et al.
Publicado: (2020)

Activity and Safety of Tegafur, Gimeracil, and Oteracil Potassium for Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
por: Zhang, Ximing, et al.
Publicado: (2021)

Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassium in treating recurrent esophagus cancer
por: Jiao, Yuyan, et al.
Publicado: (2016)

Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
por: Nakako, Soichiro, et al.
Publicado: (2021)

Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2022)

Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report
por: Qu, Fan-Jie, et al.
Publicado: (2023)

Safety of alternate-day treatment with TS-1(TM) (tegafur/gimeracil/oteracil) in tumor-bearing dogs: a pilot study
por: NISHIYAMA, Yuta, et al.
Publicado: (2021)

Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin
por: Qi, Jing, et al.
Publicado: (2020)

Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life
por: Liu, Shan, et al.
Publicado: (2021)

Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial
por: Zhang, Wen, et al.
Publicado: (2021)

Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies
por: Kobayakawa, Masao, et al.
Publicado: (2011)

Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1)
por: Luo, Dongcheng, et al.
Publicado: (2022)

Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial
por: Wang, Juan, et al.
Publicado: (2020)

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial
por: Yin, Yuping, et al.
Publicado: (2022)

Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
por: Yen, Chih-Chieh, et al.
Publicado: (2021)

Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan
por: Gao, Yiqiao, et al.
Publicado: (2019)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

H(2)S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets
por: Liu, Huan-Di, et al.
Publicado: (2016)

Tegafur deteriorates established cardiovascular atherosclerosis in colon cancer: A case report and review of the literature
por: Zhang, Shi-Chang, et al.
Publicado: (2019)

Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study
por: Chen, San-Chi, et al.
Publicado: (2016)

Tegafur-induced acral hyperpigmentation
por: Teixeira, Vera, et al.
Publicado: (2011)

Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
por: Chen, Po-Huang, et al.
Publicado: (2022)

Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer
por: Yasui, Masayoshi, et al.
Publicado: (2006)

Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo
por: Harada, Koji, et al.
Publicado: (2017)

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
por: Huang, Wen-Yen, et al.
Publicado: (2017)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
por: Okunaka, Mashiro, et al.
Publicado: (2021)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Therapeutic Effect of 1 M Tegafur‐0.4 M 5‐Chloro‐2,4‐dihydroxypyridine‐1 M Potassium Oxonate (S‐1) on Liver Metastasis of Xenotransplanted Human Colon Carcinoma
por: Konno, Hiroyuki, et al.
Publicado: (1999)

A Cooperative Randomized Study on Tegafur plus Mitomycin C versus Combined Tegafur and Uracil plus Mitomycin C in the Treatment of Advanced Gastric Cancer
por: Kurihara, Minoru, et al.
Publicado: (1991)

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
por: Collins, TA, et al.
Publicado: (2017)

Oral Tegafur/folinic acid chemotherapy decreases phenytoin efficacy
por: Veldhorst-Janssen, N M L, et al.
Publicado: (2004)

Tegafur-uracil-induced rapid development of advanced hepatic fibrosis
por: Honda, Shuya, et al.
Publicado: (2017)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Antineoplastics: Myelosuppression and COVID-19: case report
Publicado: (2020)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Treatment mechanism of matrine in combination with irinotecan for colon cancer
por: Duan, Ling, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4bpvpicii0uo4iksrmfvb6lc52